CD80 and lymphoma: As CD80 can directly interact with PD-L1 with either immune stimulatory or inhibitory outcomes (Pauken et al., 2021), the hierarchy and all possibility of these interactions in the various lymphoma TME need to be considered when assigning patients to ICB-based treatments.